United States (USA) Trauma Devices Market Overview, 2031

Key Insights

• The U.S. experiences a high volume of traumatic injuries annually: 42,939 traffic fatalities in 2021 and 42,795 in 2022 (NHTSA), 2.8 million nonfatal workplace injuries in 2022 (Bureau of Labor Statistics), and 3.2 million emergency department visits from sports-related injuries in 2022 (National Safety Council). These incidents frequently result in fractures and musculoskeletal injuries, driving sustained demand for trauma fixation devices.
• Johnson & Johnson leads the U.S. trauma fixation devices market with over 26.3% market share in 2024. The top five players Johnson & Johnson, Stryker, Smith+Nephew, Zimmer Biomet, and INTEGRA-collectively held 74.8% of the market in 2024.

Market Outlook

• According to the research report, "United States Trauma Devices Market Outlook, 2031," published by Bonafide Research, the United States Trauma Devices Market is anticipated to grow at more than 4.57% CAGR from 2026 to 2031.
• Long-term growth will be driven by favorable demographics, the expansion of the foot and ankle device segment, site-of-service flexibility, continuous improvements in physician training, and ongoing product innovation. The uptake of novel technologies such as 3-D printed implants is a key growth catalyst.
• However, rising competition and bulk purchasing by U.S. hospitals are putting downward pressure on average selling prices (ASPs), which will partially hinder market growth.

Policies

• The primary regulatory pathway for most trauma devices in the U.S. Manufacturers must demonstrate that their device is "substantially equivalent" to a legally marketed predicate device. In 2025, OrthoPediatrics received its 6th FDA 510(k) approval for the 3P Small-Mini System. The FDA has exempted almost all Class I devices from the premarket notification requirement.
• For novel devices without a predicate, the De Novo pathway provides a route to market. Neurovalens secured FDA De Novo approval in 2026 for its Modius Spero device designed to treat PTSD.
• FDA Breakthrough Device Designation program expedites the development and review of devices that provide more effective treatment for life-threatening or irreversibly debilitating conditions. Devices with this designation may qualify for alternative reimbursement pathways.
• Effective October 1, 2025, hospitals became eligible for NTAP reimbursement for innovative trauma technologies. AVITA Medical's RECELL received NTAP for treating non-burn acute wounds from trauma, providing hospitals with up to $4,875 in added reimbursement per case.

Trauma Burden & Treatment Statistics

• According to the National Highway Traffic Safety Administration (NHTSA), there were 42,939 traffic fatalities in 2021 and 42,795 deaths in 2022.
• The Bureau of Labor Statistics reported 2.8 million nonfatal workplace injuries in 2022, with 0.9 million cases resulting in lost workdays.
• The National Safety Council documented that sports-related injuries accounted for 3.2 million emergency department visits in 2022.
• A secondary analysis of patients admitted to a North American trauma center found that approximately 50% had blunt injuries (49.0%) versus penetrating injuries (48.2%).

Key Ecosystem Players

• The AO Foundation is a medically guided, not-for-profit organization led by an international group of surgeons specialized in the treatment of trauma and musculoskeletal disorders. It is the world's leading organization for education, innovation, and research in trauma treatment. The AO Technical Commission Trauma defines and prioritizes projects of its Global Expert Committees. DePuy Synthes (Johnson & Johnson) has a long-standing cooperation agreement with the AO Foundation.
• The American Academy of Orthopaedic Surgeons (AAOS) is the premier professional organization for orthopaedic surgeons. At AAOS 2025, Johnson & Johnson MedTech showcased its innovations in digital orthopaedics across trauma, extremities, and spine.

Industry News

• The XSTAT P15 hemorrhage control device received FDA 510(k) clearance for the treatment of narrow-entrance wounds through joint efforts by the Naval Medical Research Command (NMRC) and its medical device industry partner.
• The FDA approved the Arterial Restriction Clamp (ARC), a lightweight device developed by ARC Trauma to control carotid artery blood flow in traumatic neck injuries, enabling commercial manufacturing and distribution for combat care applications.
• Neurovalens received FDA De Novo approval for its Modius Spero device, a non-invasive treatment for post-traumatic stress disorder (PTSD), with plans to provide the therapy to veterans through the U.S. Department of Veterans Affairs.
• OrthoPediatrics received FDA approval for its 3P Small-Mini System, a versatile plate-and-screw fixation solution designed for pediatric orthopedic trauma procedures, representing the company's sixth FDA approval during the year.

Segment Analysis

United States Trauma Devices Market By Product Type
• Internal fixation devices are used in approximately 75-85% of surgically treated fracture cases in Canada, making them the most widely utilized trauma implants. More than 140,000 orthopedic trauma fixation procedures are performed annually using plates, screws, and intramedullary nails. Large trauma hospitals typically stock 500-2,000+ fixation implants to support varying fracture types and patient needs.
• External fixation devices are utilized in nearly 8-15% of severe trauma and open fracture cases across Canada. Estimated 8,000-12,000 external fixation procedures are performed annually, with adoption exceeding 40% among Grade III open fractures requiring emergency stabilization. Application duration generally ranges from 4-12 weeks before removal or definitive fixation.
• Orthobiologics and synthetic bone grafts are incorporated in approximately 15-25% of complex trauma reconstruction procedures in Canada. More than 10,000 trauma-related bone grafting procedures are performed annually, while synthetic grafts account for over 30% of graft-assisted surgeries in several tertiary care centers. Bone union success rates commonly exceed 85-95% in indicated cases.

United States Trauma Devices Market By Surgical Site / Anatomical Location
• Upper extremity injuries represent approximately 35-45% of all fracture-related trauma cases in Canada, with more than 250,000 upper limb fracture incidents reported annually. Surgical intervention rates range between 15-30%, depending on fracture complexity, with high utilization of plates, screws, and fixation systems for wrist, hand, and shoulder injuries. Rehabilitation follow-up is required in approximately 60-80% of surgically treated cases.
• Lower extremity trauma accounts for nearly 40% of major orthopedic trauma cases in Canada, with more than 200,000 lower limb fracture cases annually. Complex fractures involving the femur, tibia, and ankle result in higher implant utilization, with surgical treatment rates exceeding 50% for severe injuries. Patients undergoing lower extremity trauma procedures typically experience hospitalization periods of 3-10 days, followed by extended rehabilitation programs.
• Pelvic trauma devices are primarily used in severe injury cases, with pelvic fractures accounting for approximately 3-8% of all traumatic fractures in Canada. More than 5,000-10,000 pelvic fracture admissions occur annually, with surgical fixation required in around 20-40% of unstable pelvic injuries. Patients with complex pelvic trauma often require 7-14 days of hospitalization and prolonged rehabilitation support.

United States Trauma Devices Market By End User
• Hospitals represent the primary end users of trauma devices in Canada, with approximately 300+ facilities providing orthopedic trauma care and major trauma centers managing thousands of injury cases annually. Canadian hospitals handle more than 200,000 trauma related orthopedic procedures each year, with high volume centers performing 1,000-5,000+ trauma surgeries annually. Operating rooms dedicated to trauma services often maintain utilization rates above 75-85% during peak periods.
• Ambulatory Surgical Centers are increasingly involved in selected orthopedic trauma procedures, with Canada having hundreds of outpatient surgical facilities supporting musculoskeletal care. ASCs manage approximately 20-30% of eligible orthopedic trauma procedures, particularly minor fractures and follow-up interventions. These centers typically achieve same day discharge rates above 80% for suitable trauma cases and handle 500-2,000 orthopedic procedures annually per facility.
• Orthopedic clinics serve as key points for trauma diagnosis, post-operative management, and rehabilitation coordination across Canada, with 1,000+ specialized orthopedic and musculoskeletal care facilities operating nationwide. Clinics manage large volumes of trauma-related consultations, including hundreds of patient visits per month at high-volume centers. Follow-up care, imaging assessments, and rehabilitation referrals are involved in approximately 60-90% of orthopedic trauma cases after surgical or emergency treatment.

United States Trauma Devices Market By Material Type
• Stainless steel remains one of the most commonly used materials in trauma implants in Canada, accounting for approximately 40-50% of traditional fixation device usage. It is widely utilized in plates, screws, and wires, with tens of thousands of stainless steel implants implanted annually across orthopedic trauma procedures. Surgeon preference remains high at around 50-60% for cost-sensitive fixation applications, while implant retention periods often exceed 5-10 years in permanent fixation cases.
• Titanium and titanium alloys are increasingly adopted in Canadian trauma care due to their strength, lightweight properties, and biocompatibility, representing approximately 40-45% of advanced trauma implant utilization. These materials are preferred by many orthopedic surgeons, with adoption rates exceeding 60% in complex fracture and load bearing fixation procedures. Titanium implants demonstrate high long term retention, with many devices remaining in patients for 10+ years when removal is not clinically required.
• Bioabsorbable materials are emerging in specialized trauma applications, with adoption currently estimated at 5-10% of trauma implant procedures in Canada. Usage is concentrated in pediatric trauma, sports-related injuries and selected fracture fixation cases, with annual procedure volumes reaching several thousand cases. These materials gradually resorb over approximately 12-36 months, reducing the need for secondary implant removal procedures.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Trauma Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Internal Fixation Devices
• External Fixation Devices
• Orthobiologics & Synthetic Bone Grafts
• Trauma Surgical Instruments & Accessories

By Surgical Site / Anatomical Location
• Upper Extremity Trauma Devices
• Lower Extremity Trauma Devices
• Pelvic Trauma Devices
• Cranio-Maxillofacial Trauma Devices

By End User
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Orthopedic Clinics

By Material Type
• Stainless Steel
• Titanium & Titanium Alloys
• Bioabsorbable Materials
• Other Materials